Header Logo

Connection

KEVIN GAREY to Humans

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Humans.
KEVIN GAREY
Connection Strength
2.161
Humans
  1. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
    View in: PubMed
    Score: 0.027
  2. Proton pump inhibitor effect on macrophage and neutrophil function: a systematic review. Front Immunol. 2024; 15:1477993.
    View in: PubMed
    Score: 0.026
  3. Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites. Antimicrob Agents Chemother. 2024 Dec 05; 68(12):e0120624.
    View in: PubMed
    Score: 0.026
  4. Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 01; 1236:124057.
    View in: PubMed
    Score: 0.025
  5. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
    View in: PubMed
    Score: 0.025
  6. Microscopy methods for Clostridioides difficile. Anaerobe. 2024 Apr; 86:102822.
    View in: PubMed
    Score: 0.025
  7. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
    View in: PubMed
    Score: 0.025
  8. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence. Clin Infect Dis. 2023 12 05; 77(Suppl 6):S487-S496.
    View in: PubMed
    Score: 0.025
  9. Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species. Pharmacotherapy. 2023 06; 43(6):466-472.
    View in: PubMed
    Score: 0.024
  10. Emerging Options for the Prevention and Management of Clostridioides difficile Infection. Drugs. 2023 Feb; 83(2):105-116.
    View in: PubMed
    Score: 0.023
  11. Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 01 03; 6(1):e2253570.
    View in: PubMed
    Score: 0.023
  12. Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies. Gut Microbes. 2023 Jan-Dec; 15(1):2223345.
    View in: PubMed
    Score: 0.023
  13. Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clin Infect Dis. 2022 09 30; 75(7):1164-1170.
    View in: PubMed
    Score: 0.023
  14. Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis. Eur J Clin Microbiol Infect Dis. 2022 Oct; 41(10):1207-1213.
    View in: PubMed
    Score: 0.022
  15. Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers. Anaerobe. 2022 Oct; 77:102617.
    View in: PubMed
    Score: 0.022
  16. Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection. Antimicrob Agents Chemother. 2022 08 16; 66(8):e0224421.
    View in: PubMed
    Score: 0.022
  17. Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence. Ann Pharmacother. 2023 02; 57(2):184-192.
    View in: PubMed
    Score: 0.022
  18. A Vancomycin HPLC Assay for Use in Gut Microbiome Research. Microbiol Spectr. 2022 06 29; 10(3):e0168821.
    View in: PubMed
    Score: 0.022
  19. Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings. Anaerobe. 2022 Jun; 75:102543.
    View in: PubMed
    Score: 0.022
  20. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med. 2022 02; 43(1):28-38.
    View in: PubMed
    Score: 0.022
  21. Antibiotic Therapies for Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc. 2021 Nov 17; 10(Supplement_3):S52-S57.
    View in: PubMed
    Score: 0.021
  22. Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
    View in: PubMed
    Score: 0.021
  23. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
    View in: PubMed
    Score: 0.021
  24. Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. Curr HIV Res. 2021; 19(1):61-72.
    View in: PubMed
    Score: 0.020
  25. Recent developments in antimicrobial therapy for gastrointestinal infections. Curr Opin Gastroenterol. 2021 01; 37(1):30-36.
    View in: PubMed
    Score: 0.020
  26. A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 12 01; 75(12):3635-3643.
    View in: PubMed
    Score: 0.020
  27. Factors associated with abnormal glucose readings in a pharmacy-led community health fair using the ADA risk assessment tool. J Am Pharm Assoc (2003). 2021 Mar-Apr; 61(2):174-180.
    View in: PubMed
    Score: 0.020
  28. Antibiotic utilization within 18 community hospitals in the United States: A 5-year analysis. Pharmacoepidemiol Drug Saf. 2021 04; 30(4):403-408.
    View in: PubMed
    Score: 0.020
  29. Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. Clin Infect Dis. 2020 08 22; 71(5):1140-1141.
    View in: PubMed
    Score: 0.020
  30. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
    View in: PubMed
    Score: 0.019
  31. Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2020 Apr; 62:102142.
    View in: PubMed
    Score: 0.019
  32. Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
    View in: PubMed
    Score: 0.018
  33. Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clin Infect Dis. 2019 05 17; 68(11):1887-1893.
    View in: PubMed
    Score: 0.018
  34. A systematic approach to optimize electronic health record medication alerts in a health system. Am J Health Syst Pharm. 2019 Apr 08; 76(8):530-536.
    View in: PubMed
    Score: 0.018
  35. Economic health care costs of blood culture contamination: A systematic review. Am J Infect Control. 2019 08; 47(8):963-967.
    View in: PubMed
    Score: 0.018
  36. Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis. J Clin Microbiol. 2019 01; 57(1).
    View in: PubMed
    Score: 0.017
  37. Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy. Am J Health Syst Pharm. 2018 Jun 01; 75(11 Supplement 2):S51-S57.
    View in: PubMed
    Score: 0.017
  38. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. J Glob Antimicrob Resist. 2018 12; 15:41-47.
    View in: PubMed
    Score: 0.017
  39. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.017
  40. Accelerate PhenoTestTM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. Ann Pharmacother. 2018 08; 52(8):754-762.
    View in: PubMed
    Score: 0.017
  41. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 09; 14:58-64.
    View in: PubMed
    Score: 0.016
  42. Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces and patients. J Hosp Infect. 2018 Jan; 98(1):96-101.
    View in: PubMed
    Score: 0.016
  43. Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection. Antimicrob Agents Chemother. 2017 06; 61(6).
    View in: PubMed
    Score: 0.016
  44. Mechanisms for floor surfaces or environmental ground contamination to cause human infection: a systematic review. Epidemiol Infect. 2017 01; 145(2):347-357.
    View in: PubMed
    Score: 0.015
  45. Shoe soles as a potential vector for pathogen transmission: a systematic review. J Appl Microbiol. 2016 Nov; 121(5):1223-1231.
    View in: PubMed
    Score: 0.015
  46. Benchmarking and medication error rates. Am J Health Syst Pharm. 2016 Jun 01; 73(11):746.
    View in: PubMed
    Score: 0.015
  47. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul; 93(3):286-9.
    View in: PubMed
    Score: 0.014
  48. Evaluating pharmacy leader development through the seven action logics. Am J Health Syst Pharm. 2016 Jan 15; 73(2):82-5.
    View in: PubMed
    Score: 0.014
  49. Frequency of and risk factors for medication errors by pharmacists during order verification in a tertiary care medical center. Am J Health Syst Pharm. 2015 Sep 01; 72(17):1471-4.
    View in: PubMed
    Score: 0.014
  50. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
    View in: PubMed
    Score: 0.014
  51. Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole. Antimicrob Agents Chemother. 2015 Oct; 59(10):6113-6.
    View in: PubMed
    Score: 0.014
  52. Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. Am J Health Syst Pharm. 2015 Jul 15; 72(14):1204-8.
    View in: PubMed
    Score: 0.014
  53. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
    View in: PubMed
    Score: 0.014
  54. Pharmacy Practice Model Initiative task force report: Improving participation in a survey on hospital pharmacy practices in Texas. Am J Health Syst Pharm. 2015 Jun 15; 72(12):1053-7.
    View in: PubMed
    Score: 0.014
  55. Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci. 2015 Apr; 349(4):316-20.
    View in: PubMed
    Score: 0.013
  56. Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services. Am J Health Syst Pharm. 2015 Apr 01; 72(7):568-72.
    View in: PubMed
    Score: 0.013
  57. Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. Ann Lab Med. 2015 May; 35(3):306-13.
    View in: PubMed
    Score: 0.013
  58. Assessment of Antimicrobial Stewardship Activities in a Large Metropolitan Area. J Pharm Pract. 2016 Jun; 29(3):188-93.
    View in: PubMed
    Score: 0.013
  59. Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. Diagn Microbiol Infect Dis. 2015 Jan; 81(1):4-8.
    View in: PubMed
    Score: 0.013
  60. Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan; 62(1):80-4.
    View in: PubMed
    Score: 0.013
  61. Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia. 2015 Feb; 179(1-2):87-93.
    View in: PubMed
    Score: 0.013
  62. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014; 9(7):e102848.
    View in: PubMed
    Score: 0.013
  63. Education, training, and academic experience of newly hired, first-time pharmacy faculty members. Am J Pharm Educ. 2014 Jun 17; 78(5):92.
    View in: PubMed
    Score: 0.013
  64. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
    View in: PubMed
    Score: 0.013
  65. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun; 48(6):683-90.
    View in: PubMed
    Score: 0.013
  66. Investigation of potentially pathogenic Clostridium difficile contamination in household environs. Anaerobe. 2014 Jun; 27:31-3.
    View in: PubMed
    Score: 0.013
  67. A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy. Am J Pharm Educ. 2013 Nov 12; 77(9):200.
    View in: PubMed
    Score: 0.012
  68. Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis. 2013 Dec; 77(4):324-6.
    View in: PubMed
    Score: 0.012
  69. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep; 85(1):28-32.
    View in: PubMed
    Score: 0.012
  70. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. Drugs Today (Barc). 2013 Apr; 49(4):239-52.
    View in: PubMed
    Score: 0.012
  71. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr; 83(4):294-9.
    View in: PubMed
    Score: 0.012
  72. Pilot of a patient-centered pharmacy practice model. Am J Health Syst Pharm. 2012 Nov 01; 69(21):1860-1.
    View in: PubMed
    Score: 0.011
  73. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb; 68(2):438-43.
    View in: PubMed
    Score: 0.011
  74. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1086-96.
    View in: PubMed
    Score: 0.011
  75. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
    View in: PubMed
    Score: 0.011
  76. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012 Apr; 343(4):277-80.
    View in: PubMed
    Score: 0.011
  77. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun; 56(6):3239-43.
    View in: PubMed
    Score: 0.011
  78. Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012 Feb; 6(1):17-23.
    View in: PubMed
    Score: 0.011
  79. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb; 32(2):129-34.
    View in: PubMed
    Score: 0.011
  80. Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses. 2012 May; 28(5):454-9.
    View in: PubMed
    Score: 0.011
  81. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec; 66(12):2850-5.
    View in: PubMed
    Score: 0.011
  82. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul; 94(7):863-70.
    View in: PubMed
    Score: 0.010
  83. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health. 2011 Jul; 42(4):890-900.
    View in: PubMed
    Score: 0.010
  84. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep; 66(9):2146-51.
    View in: PubMed
    Score: 0.010
  85. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011 Sep; 79(1):23-6.
    View in: PubMed
    Score: 0.010
  86. Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent. Clin Microbiol Infect. 2011 Jun; 17(6):868-9.
    View in: PubMed
    Score: 0.010
  87. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10.
    View in: PubMed
    Score: 0.010
  88. Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol. 2010 Aug; 5(8):1153-6.
    View in: PubMed
    Score: 0.010
  89. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul; 8(7):747-60.
    View in: PubMed
    Score: 0.010
  90. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010 Sep; 54(9):3717-22.
    View in: PubMed
    Score: 0.010
  91. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010 May; 8(5):555-64.
    View in: PubMed
    Score: 0.010
  92. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010 May; 44(5):878-84.
    View in: PubMed
    Score: 0.010
  93. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010 Apr; 63(4):355-8.
    View in: PubMed
    Score: 0.010
  94. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010 Apr; 74(4):309-18.
    View in: PubMed
    Score: 0.009
  95. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4.
    View in: PubMed
    Score: 0.009
  96. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2009 Mar; 63(3):279-85.
    View in: PubMed
    Score: 0.009
  97. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009 Jan; 43(1):91-3.
    View in: PubMed
    Score: 0.009
  98. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.009
  99. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008 Dec; 70(4):298-304.
    View in: PubMed
    Score: 0.009
  100. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct; 20(5):652-4.
    View in: PubMed
    Score: 0.009
  101. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008 Oct; 70(2):142-7.
    View in: PubMed
    Score: 0.009
  102. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol. 2008 Oct; 199(4):332-7.
    View in: PubMed
    Score: 0.008
  103. Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. Pharmacotherapy. 2008 Jun; 28(6):699-706.
    View in: PubMed
    Score: 0.008
  104. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008 Jun; 42(6):827-35.
    View in: PubMed
    Score: 0.008
  105. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
    View in: PubMed
    Score: 0.008
  106. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008 Feb; 52(2):446-51.
    View in: PubMed
    Score: 0.008
  107. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007 Aug; 16(8):919-27.
    View in: PubMed
    Score: 0.008
  108. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
    View in: PubMed
    Score: 0.008
  109. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin. 2007 May; 23(5):1057-65.
    View in: PubMed
    Score: 0.008
  110. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2007 Apr; 13(4):413-8.
    View in: PubMed
    Score: 0.008
  111. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents. 2007 May; 29(5):557-62.
    View in: PubMed
    Score: 0.008
  112. Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection. 2006 Dec; 34(6):322-7.
    View in: PubMed
    Score: 0.008
  113. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007 Jan; 51(1):35-9.
    View in: PubMed
    Score: 0.008
  114. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006 Aug; 28(8):1208-1216.
    View in: PubMed
    Score: 0.007
  115. Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8.
    View in: PubMed
    Score: 0.007
  116. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother. 2006 Sep; 58(3):645-50.
    View in: PubMed
    Score: 0.007
  117. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 01; 43(1):25-31.
    View in: PubMed
    Score: 0.007
  118. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother. 2006 Jun; 40(6):1030-4.
    View in: PubMed
    Score: 0.007
  119. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006 May; 49(3):226-31.
    View in: PubMed
    Score: 0.007
  120. An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm. 2006 Apr 15; 63(8):735-9.
    View in: PubMed
    Score: 0.007
  121. Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother. 2006 Mar; 40(3):381-5.
    View in: PubMed
    Score: 0.007
  122. A quantitative PCR to detect non-toxigenic Clostridioides difficile. Microbiol Spectr. 2025 Jan 07; 13(1):e0160824.
    View in: PubMed
    Score: 0.007
  123. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
    View in: PubMed
    Score: 0.006
  124. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
    View in: PubMed
    Score: 0.006
  125. Economic consequences of unused medications in Houston, Texas. Ann Pharmacother. 2004 Jul-Aug; 38(7-8):1165-8.
    View in: PubMed
    Score: 0.006
  126. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest. 2004 Jan; 125(1):22-6.
    View in: PubMed
    Score: 0.006
  127. Increased Prevalence of Clostridioides difficile Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications. Pediatr Infect Dis J. 2024 Feb 01; 43(2):136-141.
    View in: PubMed
    Score: 0.006
  128. Involvement of immunization-certified pharmacists with immunization activities. Ann Pharmacother. 2004 Feb; 38(2):226-31.
    View in: PubMed
    Score: 0.006
  129. A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0034923.
    View in: PubMed
    Score: 0.006
  130. Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms. NPJ Biofilms Microbiomes. 2023 08 03; 9(1):54.
    View in: PubMed
    Score: 0.006
  131. Surveillance of Clostridioides difficile Antimicrobial Resistance in the United States. Clin Infect Dis. 2023 06 08; 76(11):2038-2039.
    View in: PubMed
    Score: 0.006
  132. The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
    View in: PubMed
    Score: 0.006
  133. Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. Lancet Infect Dis. 2023 07; 23(7):e259-e265.
    View in: PubMed
    Score: 0.006
  134. Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial. Clin Infect Dis. 2023 02 08; 76(3):e1195-e1201.
    View in: PubMed
    Score: 0.006
  135. Stool Interleukin-1? Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea. Clin Infect Dis. 2023 02 08; 76(3):e1467-e1475.
    View in: PubMed
    Score: 0.006
  136. Baseline stool toxin concentration is associated with risk of recurrence in children with Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2023 09; 44(9):1403-1409.
    View in: PubMed
    Score: 0.006
  137. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest. 2003 Jan; 123(1):261-5.
    View in: PubMed
    Score: 0.006
  138. Fusobacteria behaving badly: Masquerading strains of strictly anaerobic Escherichiacoli misidentified due to the deletion of the hemB gene. Anaerobe. 2023 Feb; 79:102682.
    View in: PubMed
    Score: 0.006
  139. Higher In Vivo Fecal Concentrations of Clostridioides difficile Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection. Clin Infect Dis. 2022 11 30; 75(11):2019-2022.
    View in: PubMed
    Score: 0.006
  140. Stool Toxin Concentration Does Not Distinguish Clostridioides difficile Infection from Colonization in Children Less Than 3 Years of Age. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):454-458.
    View in: PubMed
    Score: 0.006
  141. Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection. Clin Infect Dis. 2022 07 06; 74(12):2142-2149.
    View in: PubMed
    Score: 0.006
  142. Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol. 2022 10; 43(10):1339-1344.
    View in: PubMed
    Score: 0.005
  143. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy. 2001 Oct; 21(10):1204-22.
    View in: PubMed
    Score: 0.005
  144. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 09 07; 73(5):e1029-e1044.
    View in: PubMed
    Score: 0.005
  145. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 09 07; 73(5):755-757.
    View in: PubMed
    Score: 0.005
  146. The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests. J Clin Microbiol. 2021 08 18; 59(9):e0058521.
    View in: PubMed
    Score: 0.005
  147. Cunninghamella bertholletiae infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature. Pharmacotherapy. 2001 Jul; 21(7):855-60.
    View in: PubMed
    Score: 0.005
  148. Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. Pharmacotherapy. 2001 Jun; 21(6):748-50.
    View in: PubMed
    Score: 0.005
  149. A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains. Microb Genom. 2021 06; 7(6).
    View in: PubMed
    Score: 0.005
  150. The metabolic profile of Bifidobacterium dentium reflects its status as a human gut commensal. BMC Microbiol. 2021 05 24; 21(1):154.
    View in: PubMed
    Score: 0.005
  151. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clin Infect Dis. 2021 05 18; 72(10):e460-e465.
    View in: PubMed
    Score: 0.005
  152. Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes. 2021 Jan-Dec; 13(1):1-18.
    View in: PubMed
    Score: 0.005
  153. Pharmacist intervention program for hospitalized patients with HIV infection. Am J Health Syst Pharm. 2000 Dec 15; 57(24):2283-4.
    View in: PubMed
    Score: 0.005
  154. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000 Dec; 118(6):1826-7.
    View in: PubMed
    Score: 0.005
  155. Knowledge and self-perception comparisons between students with and without prior technician experience in community pharmacy lab courses. Curr Pharm Teach Learn. 2021 03; 13(3):279-287.
    View in: PubMed
    Score: 0.005
  156. A survey to assess experiences and social support of underrepresented minority doctor of pharmacy students. Curr Pharm Teach Learn. 2021 03; 13(3):245-254.
    View in: PubMed
    Score: 0.005
  157. Fusobacteriumnucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus. Gastroenterology. 2021 03; 160(4):1301-1314.e8.
    View in: PubMed
    Score: 0.005
  158. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig Dis Sci. 2021 10; 66(10):3303-3306.
    View in: PubMed
    Score: 0.005
  159. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
    View in: PubMed
    Score: 0.005
  160. Human-Derived Bifidobacterium dentium Modulates the Mammalian Serotonergic System and Gut-Brain Axis. Cell Mol Gastroenterol Hepatol. 2021; 11(1):221-248.
    View in: PubMed
    Score: 0.005
  161. Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype. Clin Infect Dis. 2020 06 10; 70(12):2628-2633.
    View in: PubMed
    Score: 0.005
  162. Using the Theory of Planned Behavior to Evaluate Factors That Influence PharmD Students' Intention to Attend Lectures. Am J Pharm Educ. 2020 05; 84(5):7550.
    View in: PubMed
    Score: 0.005
  163. Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis. Am J Physiol Gastrointest Liver Physiol. 2020 05 01; 318(5):G870-G888.
    View in: PubMed
    Score: 0.005
  164. Program development of a preceptor bootcamp for operational pharmacy preceptors. Am J Health Syst Pharm. 2020 Feb 19; 77(Supplement_1):S2-S7.
    View in: PubMed
    Score: 0.005
  165. Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrob Agents Chemother. 2019 12 20; 64(1).
    View in: PubMed
    Score: 0.005
  166. Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem Clin Microbiol Rev. 2019 12 18; 33(1).
    View in: PubMed
    Score: 0.005
  167. Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types. Clin Microbiol Infect. 2020 May; 26(5):646.e1-646.e8.
    View in: PubMed
    Score: 0.005
  168. Combating resistance while maintaining innovation: the future of antimicrobial stewardship. Future Microbiol. 2019 10; 14:1331-1341.
    View in: PubMed
    Score: 0.005
  169. Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. Anaerobe. 2019 Aug; 58:22-29.
    View in: PubMed
    Score: 0.005
  170. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother. 1999 May; 43(5):1152-5.
    View in: PubMed
    Score: 0.004
  171. Ridinilazole for the treatment of Clostridioides difficile infection. Expert Opin Investig Drugs. 2019 Apr; 28(4):303-310.
    View in: PubMed
    Score: 0.004
  172. Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
    View in: PubMed
    Score: 0.004
  173. Intravenous azithromycin. Ann Pharmacother. 1999 Feb; 33(2):218-28.
    View in: PubMed
    Score: 0.004
  174. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection. Antimicrob Agents Chemother. 2019 02; 63(2).
    View in: PubMed
    Score: 0.004
  175. Trovafloxacin: an overview. Pharmacotherapy. 1999 Jan; 19(1):21-34.
    View in: PubMed
    Score: 0.004
  176. Reply to Fabre et al. Clin Infect Dis. 2018 11 28; 67(12):1958-1959.
    View in: PubMed
    Score: 0.004
  177. Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
    View in: PubMed
    Score: 0.004
  178. Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms. J Clin Gastroenterol. 2018 08; 52(7):648-654.
    View in: PubMed
    Score: 0.004
  179. In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. J Clin Microbiol. 2018 08; 56(8).
    View in: PubMed
    Score: 0.004
  180. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis. 2018 05 17; 66(11):1678-1686.
    View in: PubMed
    Score: 0.004
  181. Azathioprine hypersensitivity reaction in a patient with ulcerative colitis. Ann Pharmacother. 1998 Apr; 32(4):425-8.
    View in: PubMed
    Score: 0.004
  182. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 03 19; 66(7):e1-e48.
    View in: PubMed
    Score: 0.004
  183. Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clin Microbiol Infect. 2018 Nov; 24(11):1190-1194.
    View in: PubMed
    Score: 0.004
  184. Investigating inpatient medication administration using the theory of planned behavior. Am J Health Syst Pharm. 2017 Dec 15; 74(24):2065-2070.
    View in: PubMed
    Score: 0.004
  185. Possible interaction between imipramine and butalbital. Pharmacotherapy. 1997 Sep-Oct; 17(5):1041-2.
    View in: PubMed
    Score: 0.004
  186. Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. Clin Vaccine Immunol. 2017 Aug; 24(8).
    View in: PubMed
    Score: 0.004
  187. Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
    View in: PubMed
    Score: 0.004
  188. Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
    View in: PubMed
    Score: 0.004
  189. Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):754-758.
    View in: PubMed
    Score: 0.004
  190. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 09; 50(8):631-7.
    View in: PubMed
    Score: 0.004
  191. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug; 48(2):137-43.
    View in: PubMed
    Score: 0.004
  192. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
    View in: PubMed
    Score: 0.004
  193. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
    View in: PubMed
    Score: 0.004
  194. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May; 71(5):1245-51.
    View in: PubMed
    Score: 0.004
  195. Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review. Nutr Clin Pract. 2016 Apr; 31(2):171-9.
    View in: PubMed
    Score: 0.004
  196. Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. Epidemiol Infect. 2016 Jan; 144(1):189-97.
    View in: PubMed
    Score: 0.003
  197. Reply to Bauer and Goff. Clin Infect Dis. 2015 Aug 01; 61(3):487-8.
    View in: PubMed
    Score: 0.003
  198. A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One. 2015; 10(4):e0123405.
    View in: PubMed
    Score: 0.003
  199. Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015; 10(4):e0124235.
    View in: PubMed
    Score: 0.003
  200. Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology. J Clin Microbiol. 2015 Apr; 53(4):1192-7.
    View in: PubMed
    Score: 0.003
  201. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15; 60(6):892-9.
    View in: PubMed
    Score: 0.003
  202. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014 Jun; 35(6):667-73.
    View in: PubMed
    Score: 0.003
  203. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr; 21(4):509-17.
    View in: PubMed
    Score: 0.003
  204. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013 Jun; 57(6):2690-3.
    View in: PubMed
    Score: 0.003
  205. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013 Apr; 56(7):1059-60.
    View in: PubMed
    Score: 0.003
  206. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15; 68(22):2170-4.
    View in: PubMed
    Score: 0.003
  207. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infection. J Hosp Infect. 2011 Feb; 77(2):172-3.
    View in: PubMed
    Score: 0.003
  208. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm. 2010 Aug; 67(15):e34-42.
    View in: PubMed
    Score: 0.002
  209. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs. 2010 Jul; 19(7):825-36.
    View in: PubMed
    Score: 0.002
  210. Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians. Am J Health Syst Pharm. 2010 Feb 01; 67(3):231-8.
    View in: PubMed
    Score: 0.002
  211. Clostridium difficile-related death rates in Texas 1999-2005. J Infect. 2009 Nov; 59(5):303-7.
    View in: PubMed
    Score: 0.002
  212. Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct; 31(5):565.
    View in: PubMed
    Score: 0.002
  213. Automated system to identify Clostridium difficile infection among hospitalised patients. J Hosp Infect. 2009 Aug; 72(4):337-41.
    View in: PubMed
    Score: 0.002
  214. Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm. 2008 Nov 15; 65(22):e72-9.
    View in: PubMed
    Score: 0.002
  215. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis. 2008 Oct; 21(5):500-7.
    View in: PubMed
    Score: 0.002
  216. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):964-8.
    View in: PubMed
    Score: 0.002
  217. Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. Pharmacotherapy. 2007 May; 27(5):729-33.
    View in: PubMed
    Score: 0.002
  218. Pharmacists' perceptions of the effectiveness of antimicrobial control programs. Am J Health Syst Pharm. 2006 Dec 15; 63(24):2504-8.
    View in: PubMed
    Score: 0.002
  219. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect. 2007 Jan; 65(1):42-6.
    View in: PubMed
    Score: 0.002
  220. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006 May; 101(5):1112-6.
    View in: PubMed
    Score: 0.002
  221. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005 Apr; 3(2):201-11.
    View in: PubMed
    Score: 0.002
  222. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005 Apr; 27(2):81-2.
    View in: PubMed
    Score: 0.002
  223. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. Diagn Microbiol Infect Dis. 2002 Sep; 44(1):59-61.
    View in: PubMed
    Score: 0.001
  224. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. Clin Transplant. 2001 Oct; 15(5):297-308.
    View in: PubMed
    Score: 0.001
  225. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med. 2001 Sep 01; 164(5):731-7.
    View in: PubMed
    Score: 0.001
  226. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001 Sep; 21(9):1107-14.
    View in: PubMed
    Score: 0.001
  227. Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes. Antimicrob Agents Chemother. 1999 Oct; 43(10):2547-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.